Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Article uri icon

Overview

publication date

  • May 12, 2015

Research

keywords

  • Immunoglobulin Light Chains
  • Multiple Myeloma

Identity

Scopus Document Identifier

  • 84947583575

Digital Object Identifier (DOI)

  • 10.3109/10428194.2015.1020801

PubMed ID

  • 25699653

Additional Document Info

volume

  • 56

issue

  • 10